All these considerations contributed to elect HIF-1α not only as an early biomarker of responsiveness to TMZ [9], but also as a biomarker of CMA switch on/off in glioma, being crucial for glioma cell responsiveness to TMZ treatment. The gene discussed is HIF1A; the disease is glioma.